Drugs / EDOTREOTIDE
EDOTREOTIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00978211 | Sep 1997 → Sep 2013 | neuroendocrine neoplasm | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDOTREOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL408350 ↗ |
| Known as | DOTA-TOC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00978211 ↗ |
| Known as | Edotreotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL408350 ↗ |
| Known as | SMT 487 | ChEMBL registry synonym — accepted as the source's own label CHEMBL408350 ↗ |
| Modality | Small molecule | — CHEMBL408350 ↗ |
| Route | Intravenous | “DOTA-TOC is administered intravenously” NCT00978211 ↗ |